QQQ   444.17 (-0.15%)
AAPL   171.46 (-1.07%)
MSFT   420.29 (-0.27%)
META   488.07 (-1.17%)
GOOGL   150.83 (-0.03%)
AMZN   180.47 (+0.36%)
TSLA   176.87 (-1.65%)
NVDA   905.13 (+0.29%)
NIO   4.54 (-2.78%)
AMD   180.63 (+0.58%)
BABA   72.50 (+1.27%)
T   17.68 (+0.74%)
F   13.24 (+1.38%)
MU   117.73 (-1.18%)
CGC   9.12 (-4.50%)
GE   174.95 (-2.87%)
DIS   122.77 (+1.48%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.23 (+0.99%)
XOM   116.12 (+1.00%)
QQQ   444.17 (-0.15%)
AAPL   171.46 (-1.07%)
MSFT   420.29 (-0.27%)
META   488.07 (-1.17%)
GOOGL   150.83 (-0.03%)
AMZN   180.47 (+0.36%)
TSLA   176.87 (-1.65%)
NVDA   905.13 (+0.29%)
NIO   4.54 (-2.78%)
AMD   180.63 (+0.58%)
BABA   72.50 (+1.27%)
T   17.68 (+0.74%)
F   13.24 (+1.38%)
MU   117.73 (-1.18%)
CGC   9.12 (-4.50%)
GE   174.95 (-2.87%)
DIS   122.77 (+1.48%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.23 (+0.99%)
XOM   116.12 (+1.00%)
QQQ   444.17 (-0.15%)
AAPL   171.46 (-1.07%)
MSFT   420.29 (-0.27%)
META   488.07 (-1.17%)
GOOGL   150.83 (-0.03%)
AMZN   180.47 (+0.36%)
TSLA   176.87 (-1.65%)
NVDA   905.13 (+0.29%)
NIO   4.54 (-2.78%)
AMD   180.63 (+0.58%)
BABA   72.50 (+1.27%)
T   17.68 (+0.74%)
F   13.24 (+1.38%)
MU   117.73 (-1.18%)
CGC   9.12 (-4.50%)
GE   174.95 (-2.87%)
DIS   122.77 (+1.48%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.23 (+0.99%)
XOM   116.12 (+1.00%)
QQQ   444.17 (-0.15%)
AAPL   171.46 (-1.07%)
MSFT   420.29 (-0.27%)
META   488.07 (-1.17%)
GOOGL   150.83 (-0.03%)
AMZN   180.47 (+0.36%)
TSLA   176.87 (-1.65%)
NVDA   905.13 (+0.29%)
NIO   4.54 (-2.78%)
AMD   180.63 (+0.58%)
BABA   72.50 (+1.27%)
T   17.68 (+0.74%)
F   13.24 (+1.38%)
MU   117.73 (-1.18%)
CGC   9.12 (-4.50%)
GE   174.95 (-2.87%)
DIS   122.77 (+1.48%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.23 (+0.99%)
XOM   116.12 (+1.00%)
NASDAQ:PRPH

ProPhase Labs (PRPH) Stock Price, News & Analysis

$6.52
+0.26 (+4.15%)
(As of 01:43 PM ET)
Today's Range
$6.23
$6.52
50-Day Range
$4.47
$6.29
52-Week Range
$4.05
$9.94
Volume
12,794 shs
Average Volume
25,561 shs
Market Capitalization
$117.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

ProPhase Labs MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
70.3% Upside
$11.00 Price Target
Short Interest
Healthy
1.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of ProPhase Labs in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.73) to ($0.88) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.41 out of 5 stars

Medical Sector

574th out of 939 stocks

Pharmaceutical Preparations Industry

267th out of 433 stocks

PRPH stock logo

About ProPhase Labs Stock (NASDAQ:PRPH)

ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also offers contract manufacturing services, such as consumer product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, it is involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

PRPH Stock Price History

PRPH Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
ProPhase Labs's Earnings: A Preview
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
PRPH Mar 2024 5.000 put
ProPhase Dips on Moving Karkus up Ladder
ProPhase Labs Inc (PRPH)
See More Headlines
Receive PRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRPH
Employees
129
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+75.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$18.46 million
Pretax Margin
-26.03%

Debt

Sales & Book Value

Annual Sales
$122.65 million
Cash Flow
$1.44 per share
Book Value
$3.91 per share

Miscellaneous

Free Float
13,335,000
Market Cap
$112.99 million
Optionable
Optionable
Beta
-0.34
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Ted William Karkus (Age 65)
    Chairman & CEO
    Comp: $902.2k
  • Mr. Jed A. Latkin (Age 50)
    Chief Operating Officer & Head of Finance Department
  • Mr. Robert A. Morse Jr. (Age 49)
    Controller, Principal Financial Officer & Principal Accounting Officer
  • Mr. Sergio Miralles
    Executive VP & Chief Information Officer
  • Mr. Jason Karkus
    President of Nebula Genomics
  • Mr. Kamal Obbad
    Senior VP and Director of Sales & Marketing - Nebula Genomics

PRPH Stock Analysis - Frequently Asked Questions

Should I buy or sell ProPhase Labs stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PRPH shares.
View PRPH analyst ratings
or view top-rated stocks.

What is ProPhase Labs' stock price target for 2024?

1 brokerages have issued 12-month price targets for ProPhase Labs' shares. Their PRPH share price targets range from $11.00 to $11.00. On average, they anticipate the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 70.3% from the stock's current price.
View analysts price targets for PRPH
or view top-rated stocks among Wall Street analysts.

How have PRPH shares performed in 2024?

ProPhase Labs' stock was trading at $4.52 at the beginning of the year. Since then, PRPH shares have increased by 42.9% and is now trading at $6.46.
View the best growth stocks for 2024 here
.

Are investors shorting ProPhase Labs?

ProPhase Labs saw a decrease in short interest in March. As of March 15th, there was short interest totaling 248,200 shares, a decrease of 16.9% from the February 29th total of 298,500 shares. Based on an average daily volume of 26,100 shares, the short-interest ratio is currently 9.5 days. Approximately 1.8% of the shares of the stock are short sold.
View ProPhase Labs' Short Interest
.

How were ProPhase Labs' earnings last quarter?

ProPhase Labs, Inc. (NASDAQ:PRPH) released its earnings results on Friday, November, 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by $0.33. The firm earned $9.47 million during the quarter, compared to analysts' expectations of $9.08 million. ProPhase Labs had a negative net margin of 16.70% and a negative trailing twelve-month return on equity of 17.51%. During the same period last year, the business posted ($0.05) earnings per share.

What is Ted Karkus' approval rating as ProPhase Labs' CEO?

2 employees have rated ProPhase Labs Chief Executive Officer Ted Karkus on Glassdoor.com. Ted Karkus has an approval rating of 100% among the company's employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ProPhase Labs own?
Who are ProPhase Labs' major shareholders?

ProPhase Labs' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.38%), Vanguard Group Inc. (3.38%), Perritt Capital Management Inc. (0.48%), Northern Trust Corp (0.25%), Goldman Sachs Group Inc. (0.21%) and Goldman Sachs Group Inc. (0.21%).
View institutional ownership trends
.

How do I buy shares of ProPhase Labs?

Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRPH) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners